Clinical trials have started in the UK for a coronavirus vaccine being developed in West Lothian.
Valneva’s candidate will initially be tested on 150 volunteers at four National Institute for Health Research (NIHR) testing sites in Birmingham, Bristol, Newcastle and Southampton.
The vaccine is being developed in Livingston and the UK Government has pre-ordered 60 million doses.
READ MORE: Care home vaccinations begin today
Business Secretary Alok Sharma said: “As we take the monumental steps in rolling out the first Covid-19 vaccine, we must remember that we need to have a range of vaccines available to protect the British public now and long into the future.
“Today we have more welcome news that life-saving clinical trials will begin across the country to test the safety and effectiveness of Valneva’s vaccine, which is being clinically developed right here in the UK.
“Having visited Valneva’s state-of-the art facility in the summer, I have seen first-hand the incredible work our scientists and researchers are doing to develop this vaccine.”
The trials will show whether the vaccine produces a safe and effective immune response against Covid-19.
Many vaccines are now in development (stock pic)
Larger tests will be planned for April 2021 if these are successful, with more than 4,000 UK volunteers taking two doses.
The UK Government has already pre-ordered the candidate, which could be made available by the end of 2021.
Valneva will potentially have the capacity to supply up to 250 million vaccine doses to the UK and internationally.
READ MORE: Covid vaccine - Who gets it first in Scotland and how does it work?
Thomas Lingelbach, the company’s CEO, said: “Our teams have been working extremely hard to develop our differentiated vaccine candidate and I would like to thank them, as well as the UK Government, for their dedication and support.
“While conducting our first clinical trials, we are already ramping up our manufacturing capacities and commencing production at full-scale so that we can make the vaccine widely available across the world assuming the vaccine is safe and effective.”
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules hereLast Updated:
Report this comment Cancel